Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Dyne Therapeutics, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on improving the lives of individuals with genetically driven neuromuscular diseases [1] Company Overview - Dyne Therapeutics is a clinical-stage company dedicated to delivering functional improvements for individuals with genetically driven neuromuscular diseases [3] - The company is developing therapeutics targeting muscle and the central nervous system (CNS) to address the root causes of diseases [3] - Current clinical programs include myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), with preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [3]